Shots:
- 4DMT has granted Otsuka exclusive rights to develop & commercialize 4D-150 for retinal vascular diseases, incl. wet age-related macular degeneration (wet AMD) & diabetic macular edema (DME) in Japan, China, Australia & other APAC markets, while retaining rights in other regions
- As per the deal, Otsuka will lead all regulatory & commercialization efforts in its licensed territories, while 4DMT will lead all P-III clinical activities globally, incl. within the APAC region, with APAC sites for the P-III (4FRONT-2) trial for wet AMD opening by 2025-end & Japan sites in Jan 2026
- 4DMT will receive $85M upfront & at least $50M in cost sharing over 3yrs. for global development activities, plus ~$336M in regulatory & commercial milestones & tiered double-digit royalties on net sales in Otsuka’s territories
Ref: 4DMT | Image: 4DMT & Otsuka Pharmaceutical| Press Release
Related News:- Otsuka Pharmaceutical Acquires CAN10 Immunology Program from Cantargia for ~$613M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
